Gillian Smith

发表

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.

D. Pennell, M. Cappellini, Chi-kong Li, 2010, Blood.

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major

D. Pennell, M. Cappellini, Chi-kong Li, 2012, Haematologica.

Studies on secretor status, faecal flora and the humoral immune response in ankylosing spondylitis

Gillian Smith, 1993 .

Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial

D. Pennell, R. Rajani, S. Cook, 2019, The Lancet.

Helicobacter pylori susceptibility testing by disc diffusion.

C. Mcnulty, D. Tompkins, L. Teare, 2002, The Journal of antimicrobial chemotherapy.

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

D. Pennell, M. Cappellini, Chi-kong Li, 2011, Haematologica.

The role of prolyl hydroxylases in the function of leukaemic stem cells and the development of leukaemia

Gillian Smith, 2015 .

Prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa and association with clinical outcomes in patients: an observational study.

D. Andersson, S. Satola, J. Jacob, 2021, The Journal of antimicrobial chemotherapy.

Mortality in patients with carbapenem-resistant Pseudomonas aeruginosa with and without susceptibility to traditional antipseudomonal β-lactams

S. Satola, J. Jacob, J. Howard-Anderson, 2021, JAC-antimicrobial resistance.

P41 Positive benefits of blended diet: weighing in on gastrointestinal dystonia

K. Gerasimidis, E. Buchanan, H. Duncan, 2021 .

Adaptive servo‐ventilation for central sleep apnoea in systolic heart failure: results of the major substudy of SERVE‐HF

A. Simonds, F. Zannad, W. Koenig, 2018, European journal of heart failure.

Efficacy and Safety of Deferasirox (Exjade®) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

D. Pennell, A. Taher, A. El‐Beshlawy, 2008 .

Efficacy and Safety of Deferasirox (Exjade®) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial

D. Pennell, M. Cappellini, Chi-kong Li, 2008 .

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

D. Pennell, M. Cappellini, Chi-kong Li, 2010 .

CONTINUED IMPROVEMENT IN CARDIAC T2*WITH DEFERASIROX TREATMENT OVER 2 YEARS: RESULTS FROM THE EXTENSION OF EPIC CARDIAC SUBSTUDY IN BETA-THALASSAEMIA PATIENTS WITH MYOCARDIAL SIDEROSIS

D. Pennell, M. Cappellini, Chi-kong Li, 2010 .

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

D. Pennell, M. Cappellini, Chi-kong Li, 2009 .

Development of a Broth Microdilution Method To Characterize Chlorhexidine MICs among Bacteria Collected from 2005 to 2019 at Three U.S. Sites

S. Magill, M. Kainer, S. Satola, 2023, Microbiology spectrum.

Carbapenem-resistant Enterobacterales bacteriuria and subsequent bacteremia: A population-based study

M. Farley, S. Satola, J. Jacob, 2020, Infection Control & Hospital Epidemiology.

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.

D. Pennell, M. Cappellini, Chi-kong Li, 2010, Blood.